Kenta Motomura

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen et al. · The Lancet Oncology · 2019 · 1.7K citations

Medicine, Oncology, Pharmacology +13

Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell Activation

Takeo Miyahara, Laura W. Schrum, Richard A. Rippe et al. · Journal of Biological Chemistry · 2000 · 472 citations · Full text

Life Sciences, Biochemistry, Cell Biology +13

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

Masatoshi Kudo, Kenta Motomura, Yoshiyuki Wada et al. · Liver Cancer · 2021 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.

Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen et al. · Journal of Clinical Oncology · 2018 · 96 citations

Medicine, Oncology, Pharmacotherapy +16